Executive and General Board

Executive Board 2020-2022

President

Matthias Preusser, Vienna, Austria

Matthias Preusser is a full Professor of Medical Oncology and Head of the Division of Oncology at the Medical University of Vienna. His research focuses on biomarkers and therapy in brain tumours. Recent works focus on the characterization of inflammatory infiltrates and immune checkpoint molecules in various types of brain tumours, the biology of brain metastases and identification of novel treatment options for meningiomas. Dr. Preusser is Chair-elect of the European Organisation for Research and Treatment of Cancer Brain Tumour Group and is leading or actively involved in several international clinical trials in Neuro-oncology.

Matthias Preusser, Vienna, Austria
Past-President, Chair Guidelines Committee

Martin van den Bent, Rotterdam, Netherlands

After completing my training as a neurologist I joined in 1992 the Neuro-Oncology Unit of Erasmus MC - Daniel den Hoed Cancer Center in Rotterdam, the Netherlands. This neuro-oncology unit is focused on the treatment of primary brain tumors and on neurological complications of cancer and its treatment. We  integrated in 2013 this unit with the brain tumor specialists of the department of neurosurgery into a Brain Tumor Center at Erasmus MC Cancer Center. I believe in the multidisciplinary approach, and in good clinical evidence as the corner stone of treatment. For those reasons I have been the principle investigator many large international multicenter phase II and III trials on both high and low grade glial tumors. Most of these have been conducted through the EORTC Brain Tumor Group, as this important network allows the conduct of glioma trials that make a difference. I have served between 2003 and 2009 as the chair of this internationally well recognized group, and I am currently member of the EORTC Board. I have had the honor of receiving in 2004 and in 2014 the award for excellence in clinical research by the Society for Neuro-Oncology, and to be the 2015 recipient of the 2015 ECCO Clinical Research Award. Bringing the latest research and clinical developments to patients is important, and for that reason I have established and co-chaired four editions of a bi-annual EORTC-EANO-ESMO educational course on brain tumors. We have several European professional organizations that at least partially focus on brain tumors, these need to collaborate but more importantly: EANO is pre-eminently the multidisciplinary organization for brain tumors and therefore the leading European organization for physicians and scientists devoted to neuro-oncology Recently a European Rare Cancer Network has been proposed, of which I coordinated the glioma part. A key role for EANO is obviously needed here as well.

Martin van den Bent, Rotterdam, Netherlands
Treasurer

Roberta Rudà, Turin, Italy

Dr. Roberta Rudà is a Neurologist who has been involved in neuro-oncology for up to 20 years.

Since 2011 she is Head of the Outpatient Service and Multidisciplinary Brain Tumor Board, City of Health and Science Hospital/University of Turin. She is also the Coordinator of the Neuro-Oncology Network of the  Regione Piemonte and Valle D’Aosta.

Dr. Roberta Rudà is Professor of Neuro-Oncology in the Residency Programs of Neurosurgery and Diagnostic Imaging/Radiotherapy of the University of Turin.

The major research areas are represented by primary brain tumors with particular interest in lower grade gliomas, epilepsy, and primary CNS lymphomas. Translational research, functional neuroimaging and neurological complications of cancers (in particular neoplastic meningitis and brain metastases) have been a focus of interest as well. In this regard Dr. Rudà is Principal Investigator in several international clinical trials.

Dr. Rudà is Member of the Editorial Board of Neuro-Oncology, Neuro-Oncology Practice, Journal of Neurosurgical Sciences and World Federation of Neuro-Oncology Magazine, and Reviewer for J. Neuro-Oncology, Lancet Oncology, J. Neurology and Epilepsia.

Dr. Rudà has been a Member of the Scientific Committee of EANO since 2014, and Member of the EANO Task Forces for Guidelines in PCNSL, Ependymomas, Leptomeningeal Metastases, Brain Metastases and Palliative/Supportive Care. She is Member of the RANO Groups on Leptomeningeal Metastases and Epilepsy in Brain Tumors, and of the Brain Tumor Group of EORTC.

She is Secretary of the Italian Association of Neuro-Oncology (AINO) since 2013 and she has been the chair of the Local Organizing Committee of the EANO Congress in Turin, 2014.

Roberta Rudà, Turin, Italy
EANO Executive Board Member

Anthony Chalmers, Glasgow, United Kingdom

Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice at the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving outcomes for patients with glioblastoma by combining radiotherapy with targeted drug therapies, but his research interests in radiotherapy-drug combinations extend across tumour sites including lung cancer and mesothelioma. He is Chief Investigator for a portfolio of early phase clinical trials evaluating the oral PARP inhibitor olaparib in combination with radiotherapy and/or chemotherapy in treatment of glioblastoma, and also leads the randomised phase II SYSTEMS-2 trial of radiotherapy dose escalation in mesothelioma. He is Chair of the UK’s Clinical and Translational Radiotherapy Research Working Group (CTRad) and is a scientific theme lead for the Radiotherapy-Drug Combinations Consortium (RaDCom), a joint initiative between Cancer Research UK and the UK National Cancer Research Institute. Previously a member of the Scientific Committee of the European Association for Neuro-Oncology (EANO), he sits on the Radiobiology Committee of the European Society for Therapeutic Radiation Oncology (ESTRO) and is Chair of the Scottish Radiotherapy Research Forum (ScoRRF).

Anthony Chalmers will be the EANO 2020 Meeting President

Anthony Chalmers, Glasgow, United Kingdom
EANO Executive Board Member

Asgeir Jakola, Gothenburg, Sweden

Dr. Asgeir S. Jakola is an Associate professor in Neurosurgery and a clinical active neurosurgeon with a special focus on patients with brain tumors. Dr. Jakola did his neurosurgical training in Trondheim (Norway) where he got significant experience in image-guided surgery. Since 2015 he has been clinically active in Gothenburg, Sweden.

Bringing research findings to patients and to include patients in research are both crucial important tasks. Dr. Jakola and collaborators have recently established a multidisciplinary, clinically oriented research group at Sahlgrenska Academy, Gothenburg to succeed in these tasks. This group already collaborates extensively with basic cancer researchers and engineers in addition to other national and international clinical research groups.

Dr. Jakolas main research interests include low-grade glioma, patient reported outcome, registry based and comparative effectiveness neurosurgical research. His research has had broad impact on neurosurgical management of patients with low-grade glioma.

Asgeir Jakola, Gothenburg, Sweden
EANO Executive Board Member

Simone Niclou, Luxembourg, Luxembourg

Simone P. Niclou is Deputy Director of the Department of Oncology at the Luxembourg Institute of Health (LIH) and head of the NORLUX Neuro-Oncology Laboratory at LIH (www.lih.lu). Trained as a biologist, Dr. Niclou gained a PhD in neurobiology at the Friedrich Miescher Institute in Basel, Switzerland. After postdoctoral trainings at the Neuroscience Department of the University of Pennsylvania (US) and at the Netherlands Institute for Neurosciences in Amsterdam (NL), her research interest turned to brain cancer, establishing a neuro-oncology research group in Luxembourg in 2007.

Her research is focused on the biology of diffuse gliomas with a special interest in glioma metabolism, tumour heterogeneity, glioma stem cells, tumor angiogenesis and invasion. Her lab has established unique patient-derived mouse models (orthotopic PDX models) for brain tumour research and studied mechanisms of anti-angiogenic treatment in glioblastoma. Her key motivation is to generate new insight that will be applicable for clinical translation. 

Since 2014 Dr. Niclou is an adjunct professor at the University of Bergen, Norway, and in 2015 she was nominated President of the Board of Directors of the Laboratoire national de santé, the national diagnostics laboratory in Luxembourg (www.lns.lu). She has previously served on the Scientific Board of the European Association for Neuro-Oncology (EANO) and was country representative in the council of the European Association for Cancer Research (EACR). She also regularly serves on international Advisory Boards of grant awarding bodies for cancer research throughout Europe.

Simone Niclou, Luxembourg, Luxembourg
EANO Executive Board Member, Nurse and Allied Health Professionals Representative

Karin Piil, Copenhagen, Denmark

Karin Piil has been working within neuro-oncology since 1994; as a head nurse at the Department of Neurosurgical and currently as a senior researcher at the Department of Oncology at Rigshospitalet, Copenhagen, Denmark.

She holds an international Master of Health Science, Nursing from Deakin University, Melbourne Australia and a Ph.D. on patients with high-grade glioma and the caregivers from the Faculty of Health and Medical Sciences, University of Copenhagen.

Her research has focused on patients’ and relatives´ perspectives on the high-grade glioma trajectory and coping strategies, for example related to the notion on hope and how families and networks can be involved. Current research is inspired from Linné university at Kalmar, Sweden and explores whether systematic and nurse-led family/network conversations can enhance the well-being and social support for the patient.

Karin Piil has a key interest on research on the patient and relative perspectives on the neuro-oncological disease- and treatment course, symptoms such as cognitive challenges, quality of life, family dynamics, bereaved caregivers, patients’ and relatives’ involvement in research processes and decision-making processes among patients with recurrence of malignant brain tumors.

Karin Piil wish to contribute to an even stronger development of an European neuro-oncological research agenda that brings together a multi professional perspective.

Karin Piil, Copenhagen, Denmark
EANO Executive Board Member

Patrick Roth, Zurich, Switzerland

Patrick Roth, MD, is a senior leading physician at the Department of Neurology and the coordinating physician of the Brain Tumor Center at the University Hospital Zurich. He earned his medical degree from the University of Freiburg (Germany) in 2003. He received postgraduate training in Neurology at the University of Tübingen and the University Hospital Zurich. He specializes in the interdisciplinary management of brain tumor patients with a preclinical and clinical research focus on the immunology and immunotherapy of brain tumors as well as the development of novel therapeutic strategies. He is the President of the Working Group CNS Tumors within the Swiss Group for Clinical Cancer Research and previously served on the Scientific Board of EANO. He acts as the study coordinator of the EORTC 1709/CCTG CE.8 trial, a randomized phase 3 trial for patients with newly diagnosed glioblastoma assessing the activity marizomib, a novel brain-penetrant proteasome inhibitor.

 

Patrick Roth, Zurich, Switzerland
EANO Executive Board Member

Felix Sahm, Heidelberg, Germany

Felix Sahm is neuropathologist at the Dept. of Neuropathology at the University Hospital Heidelberg and head of the molecular diagnostics branch of the department.

His research focuses on the identification of novel clinically relevant subgroups of brain tumors beyond the variants that can be distinguished by histology. Subsequently, he implements novel molecular markers accurately stratifying for these subgroups into diagnostic routine.

Dr. Sahm performs central and reference molecular neuropathology for various studies on pediatric and adult brain tumors (e.g. MNP2.0, PTT2.0, N2M2).

He has contributed to >100 publications in peer reviewed journals. These include his study elucidating that gliomas histologically presenting as oligoastrocytoma can molecularly be assigned to either astrocytoma or oligodendroglioma, the implementation of the first brain tumor-specific hybrid-capture next-generation-sequencing panel, or the study establishing the prognostic role of TERT promoter mutations in meningioma.

Currently, he investigates the molecular landscape of meningioma in order to integrate molecular markers into diagnostic work-up and treatment decisions, starting with the recently implemented DNA methylation-based grading approach to meningioma.

 

 

Felix Sahm, Heidelberg, Germany
EANO Executive Board Member

Marilena Theodorou, Nicosia, Cyprus

Dr. med. Marilena Theodorou is consultant in radiation oncology specialist for brain tumors (malignant and benign ), brain metastasis, pediatric tumors, in Bank of Cyprus Oncology Center, Nicosia Cyprus since 10/2015, she is also lecturer in the european university of cyprus for radiation oncology. Her subspecialty is Radiosurgery and Stereotactic Radiotherapy. She was born in Cyprus, studied Medicine in University of Leipzig Germany. Specialization and Work Experience  in Klinikum Rechts der Isar, Technical University of Munich, Germany with Supspecialty Radiosurgery and Stereotactic Radiotherapy. Her PhD is about meningiomas with stereotactic radiotheray and radiosurgery. Her dream :every patient-child in europe  has the opportunity for the same treatment as a patient in Germany.

Marilena Theodorou, Nicosia, Cyprus

General Board 2020-2022

Chair Youngsters Committee

Anna Berghoff, Vienna, Austria

Anna Berghoff is in medical oncology training at the Medical University of Vienna, Austria. She finished the PhD program “Clinical Neuroscience” in 2014 with the main focus on clinical and pathological prognostic factors in brain metastases

Anna Berghoff, Vienna, Austria
Chair Educational Committee

Evangelia Razis, Athens, Greece

Dr. Razis studied medicine at Northwestern University, Chicago, IL. She completed a three year medical residency at Beth Israel Medical Center, a six year Honors Program and a three year Oncology Fellowship at New York Medical College/Westchester County Medical Center. She then worked as an Instructor of Medicine in New York Medical College. Upon returning to Greece, she started working as an attending at Hygeia hospital while completing a Ph.D. in Medicine. She is currently appointed as Director in the 3rd Oncology department in Athens, Greece at “Hygeia” Hospital. In the Spring of 2016, Dr. Razis led her practice to the first ever Quality certification by ASCO for an international practice.

Dr. Razis has a strong interest in education, giving several lectures a year and teaching doctors who are in the process of specialization. She has worked voluntarily in the Sudan, in Sri Lanka, in the Honduras, in Zimbabwe, in Rwanda and in Kefalonia, Greece. Her specific interests include Breast Cancer and Neuro-oncology. She actively participates in a number of Medical Associations and cooperative groups, including ASCO, ESMO, EANO, SNO, HeCOG, National Cancer Institute, the Breast International Group, the EORTC Breast Cancer Group, the EORTC Brain Tumor Group, where she is appointed to the Quality assurance subcommittee, and Brain Tumor Funders’ Collaborative Consortium. She has published over 100 papers, has presented several abstracts-posters in international congresses and meetings and has worked on 22 chapters and courses.

Evangelia Razis, Athens, Greece
Chair Scientific Committee

Michael Platten, Mannheim, Germany

Michael Platten is Chairman of the Department of Neurology at the University Hospital in Mannheim and Head of the Department of Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center. He is a steering committee member of the German Neurooncology Working Group (NOA) and serves as a faculty member of the German Cancer Consortium and on the Mangement Board of the Helmholtz Institute for Translational Oncology (HiTRON). Michael is currently conducting early multicenter trials for the NOA. He discovered novel pathways involved in immune regulation in gliomas and pioneered the development of novel therapeutic strategies for the immunotherapy of gliomas and other types of cancer. His main scientific focus includes glioma immunogenicity, immune suppression, heterogeneity and personalized treatment strategies. Michael has published more than 130 articles in peer-reviewed journals including Nature, Nature Medicine, Science, PNAS, JCI, NEJM, Lancet Oncology and JCO.

Michael Platten, Mannheim, Germany
Chair Publishing Activity Committee

Wolfgang Wick, Heidelberg, Germany

Wolfgang Wick is Chairman of the Neurology Clinic at the University Hospital Heidelberg and Director for Neurooncology at the National Tumor Center at the University of Heidelberg, Germany.

He is currently conducting multicenter phase I-III randomized trials for the Neurooncology Working Group (NOA) of the German Cancer Society, the European Organisation for Research and Treatment of Cancer (EORTC), the EU GAPVAC consortium, as well as a number of multicenter trials with the pharmaceutical industry. He is a steering committee member of the NOA and the European Association for Neuro-Oncology (EANO), as well as chairman of the EORTC Brain Tumor Group.

His main scientific interests include resistance mechanisms, immunotherapy, biomarkers, and radiosensitization. Professor Wick has written more than 250 publications in peer-reviewed journals, such as the Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Nature, Nature Medicine, Neurology, Neuro Oncology, Annals of Neurology, The New England Journal of Medicine and Journal of Clinical Investigation.

Wolfgang Wick, Heidelberg, Germany